Skip to main content
. 2020 Nov 6;12(11):1059. doi: 10.3390/pharmaceutics12111059
AIDS Acquired immunodeficiency syndrome
WHO World Health Organization
UNAIDS The Joint United Nations Program on HIV/AIDS
HIV Human immunodeficiency virus
HAART Highly active antiretroviral therapy
ARV Antiretroviral
CNS Central nervous system
BBB Blood–brain barrier
P-gp P-glycoprotein
NLC Nanostructured lipid carriers
ATZ Atazanavir
SLN Solid lipid nanoparticle
SNEDDS Self-nanoemulsifying drug delivery system
SLB Solid–liquid binary lipid
QbD Quality by Design
BBD Box–Behnken design
RSM Response surface methodology
PDI Polydispersity index
ZP Zeta potential
EE Entrapment efficiency
LC Loading capacity
TEM Transmission electron microscopy
DSC Differential scanning calorimetry
PBS Phosphate buffer saline
HPLC High performance liquid chromatographic method
CLSM Confocal laser scanning microscopy
MTT Methylthiazoletetrazolium
H&E Hematoxylin and eosin
CV Cresyl violet
ANOVA Analysis of variance (ANOVA
GRAS Generally recognized as safe
HLB Hydrophilic–lipophilic balance